65384-99-8

Basic information

• Product Name: (4-phenyl-1,3-thiazol-2-yl)methanol
• Synonyms: (4-phenyl-1,3-thiazol-2-yl)methanol;(4-phenyl-1,3-thiazol-2-yl)methanol(SALTDATA: 0.95HCl 0.25H2O);(4-phenyl-2-thiazolyl)methanol;(4-phenylthiazol-2-yl)methanol
• CAS NO: 65384-99-8
• Molecular Formula: C₁₀H₉NOS
• Molecular Weight: 191.25
• Mol File: 65384-99-8.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 350.6±25.0 °C(Predicted)
• Appearance: /
• Density: 1.264±0.06 g/cm3(Predicted)
• PKA: 13.06±0.10(Predicted)
• CAS DataBase Reference: (4-phenyl-1,3-thiazol-2-yl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (4-phenyl-1,3-thiazol-2-yl)methanol(65384-99-8)
• EPA Substance Registry System: (4-phenyl-1,3-thiazol-2-yl)methanol(65384-99-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 65384-99-8(Hazardous Substances Data)

Usage

General Description

(4-phenyl-1,3-thiazol-2-yl)methanol, also known as 4-phenylthiazol-2-ylmethanol, is a chemical compound with the molecular formula C10H9NOS. It is a thiazole derivative with a phenyl group attached to the thiazole ring. (4-phenyl-1,3-thiazol-2-yl)methanol has been studied for its potential biological activities, including its anti-inflammatory and anti-cancer properties. It has also been used as a building block in the synthesis of various pharmaceutical and agrochemical compounds. The presence of both a thiazole and a phenyl group in the molecule makes it an interesting target for further research and potential applications in medicine and other fields.

Upstream product

• 858009-07-1 2-ethoxymethyl-4-phenyl-thiazole 
• 110704-59-1 (4-phenylthiazol-2-yl)methyl benzoate 
• 70-11-1 α-bromoacetophenone 
• 75390-44-2 4-Phenyl-2-Thiazolecarboxaldehyde 
• 40235-62-9 2-acetoxythioacetamide 
• 31877-30-2 ethyl 4-phenyl-1,3-thiazole-2-carboxylate 

Downstream Products

• 75390-44-2 4-Phenyl-2-Thiazolecarboxaldehyde 
• 65385-00-4 2-chloromethyl-4-phenylthiazole 
• 78502-79-1 2-(bromomethyl)-4-phenylthiazole 
• 110703-77-0 [4-Oxo-3-(4-phenyl-thiazol-2-ylmethyl)-3,4-dihydro-phthalazin-1-yl]-acetic acid 
• 59020-44-9 4-phenylthiazole-2-carboxylic acid 
• 1476847-59-2 2-Methoxy-6-(6-methoxy-4-((4-phenylthiazol-2-yl)methoxy)benzofuran-2-yl)imidazo[2,1-b][1,3,4]thiadiazole 

Relevant articles and documents

Design, synthesis and Structure-activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes

The free fatty acid receptor 1 (FFA1/GPR40) has attracted interest as a novel target for the treatment of type 2 diabetes. Several series of FFA1 agonists including TAK-875, the most advanced compound terminated in phase III studies due to concerns about liver toxicity, have been hampered by relatively high molecular weight and lipophilicity. Aiming to develop potent FFA1 agonists with low risk of liver toxicity by decreasing the lipophilicity, the middle phenyl of TAK-875 was replaced by 11 polar five-membered heteroaromatics. Subsequently, systematic exploration of SAR and application of molecular modeling, leads to the identification of compound 44, which was an excellent FFA1 agonist with robustly hypoglycemic effect both in normal and type 2 diabetic mice, low risks of hypoglycemia and liver toxicity even at the twice molar dose of TAK-875. Meanwhile, two important findings were noted. First, the methyl group in our thiazole series occupied a small hydrophobic subpocket which had no interactions with TAK-875. Furthermore, the agonistic activity revealed a good correlation with the dihedral angle between thiazole core and the terminal benzene ring. These results promote the understanding of ligand-binding pocket and might help to design more promising FFA1 agonists.

IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION

The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.

HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes